Familial Hypercholesterolemia
100
15
21
48
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
16 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.0%
4 terminated out of 100 trials
92.3%
+5.8% vs benchmark
18%
18 trials in Phase 3/4
33%
16 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (100)
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)
Comparing Direct vs Indirect Methods for Cascade Screening
Pediatric Reporting of Adult-Onset Genomic Results
The ORIGIN-FH Study
Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics
EAS Familial Hypercholesterolaemia Studies Collaboration
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.
Penn Family Screening for Familial Hypercholesterolemia
Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Patients With Familial Hypercholesterolemia
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers